Coherus BioSciences, Inc. (NASDAQ:CHRS) Holdings Increased by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC increased its stake in Coherus BioSciences, Inc. (NASDAQ:CHRS) by 100.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,844 shares of the biotechnology company’s stock after acquiring an additional 30,922 shares during the period. Knights of Columbus Asset Advisors LLC’s holdings in Coherus BioSciences were worth $206,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in CHRS. Ensign Peak Advisors Inc boosted its stake in Coherus BioSciences by 6.9% during the 3rd quarter. Ensign Peak Advisors Inc now owns 21,490 shares of the biotechnology company’s stock valued at $207,000 after purchasing an additional 1,390 shares in the last quarter. Federated Hermes Inc. boosted its stake in Coherus BioSciences by 55.0% during the third quarter. Federated Hermes Inc. now owns 4,223 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 1,498 shares in the last quarter. Mackenzie Financial Corp grew its holdings in Coherus BioSciences by 4.7% during the first quarter. Mackenzie Financial Corp now owns 33,671 shares of the biotechnology company’s stock worth $435,000 after acquiring an additional 1,509 shares during the period. American International Group Inc. raised its position in Coherus BioSciences by 5.6% in the second quarter. American International Group Inc. now owns 39,212 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 2,067 shares in the last quarter. Finally, Eagle Bay Advisors LLC boosted its position in shares of Coherus BioSciences by 136.1% during the 2nd quarter. Eagle Bay Advisors LLC now owns 3,891 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 2,243 shares in the last quarter. Institutional investors and hedge funds own 72.82% of the company’s stock.

Coherus BioSciences Trading Up 3.5 %

Shares of NASDAQ CHRS opened at $2.07 on Monday. Coherus BioSciences, Inc. has a one year low of $1.43 and a one year high of $8.33. The business has a 50-day moving average price of $2.39 and a two-hundred day moving average price of $2.52. The firm has a market capitalization of $234.95 million, a PE ratio of -0.81 and a beta of 0.54.

Coherus BioSciences (NASDAQ:CHRS) last released its quarterly earnings data on Wednesday, March 13th. The biotechnology company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.39). The business had revenue of $91.52 million for the quarter, compared to analysts’ expectations of $105.30 million. Research analysts anticipate that Coherus BioSciences, Inc. will post -0.56 EPS for the current year.

Analysts Set New Price Targets

CHRS has been the subject of several recent research reports. HC Wainwright cut their target price on shares of Coherus BioSciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, March 20th. Truist Financial cut their price objective on Coherus BioSciences from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, January 23rd. Finally, Robert W. Baird reduced their price objective on Coherus BioSciences from $11.00 to $9.00 and set an “outperform” rating for the company in a research note on Tuesday, January 23rd. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.29.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.